The stock is in a pronounced downtrend over the past year, with a 1-year price change of -16.19%, significantly underperforming the SPY's +20.95% gain. Currently trading at $54.87, the price sits approximately 21% above its 52-week low of $41.73 but remains 47% below its 52-week high of $104.32, indicating it is recovering from deep lows but remains far from previous highs, suggesting a potential value opportunity amidst substantial prior weakness. Recent momentum shows a sharp divergence, with a strong 1-month gain of 17.60% and a 3-month surge of 28.74%, dramatically outperforming the market's negative and positive returns over those periods, respectively; this powerful short-term rebound against the longer-term downtrend could signal a potential trend reversal or a significant bear market rally, though it follows a severe maximum drawdown of -58.96%. Key technical levels are the 52-week low at $41.73 as critical support and the 52-week high at $104.32 as major resistance; a sustained breakout above the recent recovery highs would challenge the downtrend narrative, while a breakdown below support could renew the sell-off, with the stock's extreme beta of 3.62 indicating it is over 260% more volatile than the market, necessitating outsized risk tolerance for investors.

Revenue growth is exceptionally strong but shows signs of sequential deceleration; Q4 2025 revenue reached $367.2 million, representing a massive 82.98% year-over-year increase, yet this follows even higher growth in prior quarters, with Q3 2025 revenue at $334.2 million and Q2 at $314.6 million, indicating the growth engine remains powerful but the rate of increase may be moderating from its peak. The company is deeply unprofitable, with a Q4 2025 net loss of $54.2 million, though this improved from a $79.98 million loss in Q3; the gross margin of 89.74% in Q4 is exceptionally high and expanded significantly from 61.61% in Q3, driven by a favorable revenue mix, but this is offset by substantial operating expenses, resulting in a net margin of -14.75%. Financial health is a concern due to heavy cash burn, with trailing twelve-month free cash flow deeply negative at -$404.0 million, a debt-to-equity ratio of 2.70 indicating significant leverage, and a return on equity of -49.87%, though the current ratio of 3.13 suggests adequate short-term liquidity; the company is currently dependent on external financing to fund its growth and losses, as internal cash generation is insufficient.